Ignite Creation Date:
2024-05-05 @ 12:07 PM
Last Modification Date:
2024-10-26 @ 9:20 AM
Study NCT ID:
NCT00244322
Status:
COMPLETED
Last Update Posted:
2007-05-28
First Post:
2005-10-24
Brief Title:
Effects of LY450139 Dihydrate on Subjects With Mild to Moderate Alzheimers Disease
Sponsor:
Eli Lilly and Company
Organization:
Eli Lilly and Company
Study Overview
Official Title:
LY450139 Tolerability and Biomarker Assessment in Subjects With Mild to Moderate Alzheimers Disease
Status:
COMPLETED
Status Verified Date:
2007-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purposes of this study are to determine
The safety of LY450139 dihydrate and any side effects that might be associated with it
How much LY450139 dihydrate should be given and how long it may be detected in blood
To determine if LY450139 dihydrate may have an effect on a protein found in blood called A beta This protein is studied in subjects with Alzheimers disease
To collect and store samples from blood and spinal fluid for research related to Alzheimers disease and similar neurodegenerative diseases or inflammation irritation that may provide information on how subjects respond to LY450139 or other medications
Length of study Approximately 29 weeks
Number of office visits 11 for most subjects initial visit every other week during 14 weeks of study drug treatment and 2 follow-up visits
At no cost approximately 45 eligible participants will receive
Study medication
Study-related diagnostic and laboratory evaluations
The safety of LY450139 dihydrate and any side effects that might be associated with it
How much LY450139 dihydrate should be given and how long it may be detected in blood
To determine if LY450139 dihydrate may have an effect on a protein found in blood called A beta This protein is studied in subjects with Alzheimers disease
To collect and store samples from blood and spinal fluid for research related to Alzheimers disease and similar neurodegenerative diseases or inflammation irritation that may provide information on how subjects respond to LY450139 or other medications
Length of study Approximately 29 weeks
Number of office visits 11 for most subjects initial visit every other week during 14 weeks of study drug treatment and 2 follow-up visits
At no cost approximately 45 eligible participants will receive
Study medication
Study-related diagnostic and laboratory evaluations
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| H6L-MC-LFAJ | None | None | None |